Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digi-Panc-1
2024-512128-12-01Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of digitoxin in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Region Västra Götaland. Primary endpoint: Progression-free survival at 1 year. Planned start Nov 2025; status: authorised.
02
Drugs
digitoxin
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-512128-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512128-12-01.